IXIARO®updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis
Citations Over Time
Abstract
The mosquito-borne Japanese encephalitis virus causes an estimated 50,000 cases in Asia, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. IXIARO® (Intercell AG, Vienna, Austria), an inactivated, Vero cell-derived vaccine against Japanese encephalitis was introduced in 2009. The vaccine is highly immunogenic, showing significantly higher geometric mean antibody titers compared with previous, mouse brain-derived vaccines. Postmarketing studies have confirmed the excellent safety profile. Studies on children aged 2 months to 18 years have been published. Based on these data, positive opinion from the EMA for vaccination of children has recently been given. Since a safe and effective vaccine against Japanese encephalitis is now available, outdated guidelines and recommendations have to be revised: travelers to rural areas of Asia should generally be recommended vaccination.
Related Papers
- → Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study(1996)222 cited
- → IXIARO®updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis(2013)20 cited
- Comparative Study on the Cellular Immunity Response Induced by Live Attenuated SA14-14-2 Japanese Encephalitis Vaccine and Inactivated Japanese Encephalitis Vaccine in Mice(2010)
- → IXIARO®updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis(2013)2 cited